Fractionated stereotactic body radiation therapy in the treatment of previously-irradiated recurrent head and neck carcinoma: Updated report of the university of pittsburgh experience

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 33, Issue 3, 2010, Pages 286-293

  Rwigema, Jean Claude ^a   Heron, Dwight E ^a   Ferris, Robert L ^b   Gibson, Michael ^c   Quinn, Annette ^a   Yang, Yong ^a   Ozhasoglu, Cihat ^a   Burton, Steven ^a  

^a Department of Radiation Oncology ^*  (United States)

^b Division of Head and Neck Surgery   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Cyberknife; Recurrent head and neck cancer; SBRT; Stereotactic radiosurgery; Trilogy

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; DYSGEUSIA; DYSPHAGIA; EDEMA; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEASIBILITY STUDY; FEMALE; FIBROSIS; HEAD AND NECK CARCINOMA; HEAD AND NECK SURGERY; HOARSENESS; HUMAN; HYPERPIGMENTATION; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; ODYNOPHAGIA; OVERALL SURVIVAL; PAIN; RADIATION DOSE FRACTIONATION; RADIATION RESPONSE; RADIATION SAFETY; RECURRENT CANCER; SORE THROAT; SQUAMOUS CELL CARCINOMA; STEREOTACTIC BODY RADIATION THERAPY; SURVIVAL RATE; THERAPY EFFECT; TREATMENT OUTCOME; TUMOR VOLUME; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BRACHYTHERAPY; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PAIN; RADIOSURGERY; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TUMOR BURDEN; XEROSTOMIA;

EID: 77953344380     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181aacba5     Document Type: Article

References (36)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin. 2008;58:71-96.
2. Vokes EE, Weichselbaum RR, Lippman SM, et al. Head and neck cancer. N Engl J Med. 1993;328:184-194.
3. Stell PM. Survival times in end-stage head and neck cancer. Eur J Surg Oncol. 1989;15:407-410.
4. Forastiere AA. Overview of platinum chemotherapy in head and neck cancer. Semin Oncol. 1994;21:20-27.
5. Vokes EE, Athanasiadis I. Chemotherapy of squamous cell carcinoma of head and neck: the future is now. Ann Oncol. 1996;7:15-29.
6. Clavel M, Vermorken JB, Cognetti F, et al. Randomized comparison of cisplatin, methotrexate, bleomycin, and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck: a phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol. 1994;5:521-526.
7. Forastiere AA, Metch B, Schuller DE, et al.; A Southwest Oncology Study Group. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck. J Clin Oncol. 1992;10:1245-1251.
8. Jacobs C, Lyman G, Velez-Garcia E, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 1992;10:257-263.
9. Jacobs C, Meyers F, Hendrickson C, et al.; A Northern California Oncology Study Group. A randomized phase III study of cisplatin with or without methotrexate for recurrent squamous cell carcinoma of the head and neck. Cancer. 1983;52:1563-1569.
10. Dawson LA, Myers LL, Bradford CR, et al. Conformal re-irradiation of recurrent and new primary head and neck cancer. Int J Radiat Oncol Biol Phys. 2001;50:377-385.
11. Stevens KR Jr, Britsch A, Moss WT. High-dose reirradiation of head and neck cancer with curative intent. Int J Radiat Oncol Biol Phys. 1994;29:687-698.
12. Chmura SJ, Milano MT, Haraf DJ. Reirradiation of recurrent head and neck cancers with curative intent. Semin Oncol. 2004;31:816-821.
13. Pomp J, Levendag PC, van Putten WL. Reirradiation of recurrent tumors in the head and neck. Am J Clin Oncol. 1988;11:543-549.
14. De Crevoisier R, Bourhis J, Eschwege F. Modified fractionated radiotherapy in head and neck squamous cell carcinoma (HNSCC) & re-irradiation in recurrent head and neck carcinomas. Cancer Treat Res. 2003;114:199-212.
15. Kaplan ID, Adler JR, Hicks WL, et al. Radiosurgery for palliation of base of skull recurrences from head and neck cancers. Cancer. 1992;70:1980-1984.
16. Lunsford LD, Flickinger J, Coffey RJ. Stereotactic gamma knife radiosurgery. Initial North American experience in 207 patients. Arch Neurol. 1990; 47:169-175.
17. Whyte RI, Crownover R, Murphy MJ, et al. Stereotactic radiosurgery for lung tumors: preliminary report of a phase I trial. Ann Thorac Surg. 2003;75:1097-1101.
18. King CR, Lehmann J, Adler JR, et al. CyberKnife radiotherapy for localized prostate cancer: rationale and technical feasibility. Technol Cancer Res Treat. 2003;2:25-30.
19. Ryu S, Khan M, Yin FF, et al. Image-guided radiosurgery of head and neck cancers. Otolaryngol Head Neck Surg. 2004;130:690-697.
20. Voynov G, Heron DE, Burton S, et al. Frameless stereotactic radiosurgery for recurrent head and neck carcinoma. Technol Cancer Res Treat. 2006;5:529-535.
21. Schoder H, Yeung HW, Gonen M, et al. Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion. Radiology. 2004;231:65-72.
22. Branstetter BF IV, Blodgett TM, Zimmer LA, et al. Head and neck malignancy: is PET/CT more accurate than PET or CT alone? Radiology. 2005; 235:580-586.
23. Chappell R, Nondahl DM, Fowler JF. Modeling dose and local control in radiotherapy. J Am Stat Assoc. 1995;90:829-838.
24. Fuller LM, Krasin MJ, Velasquez WS, et al. Significance of tumor size and radiation dose to local control in stage I-III diffuse large cell lymphoma treated with CHOP-Bleo and radiation. Int J Radiat Oncol Biol Phys. 1995;31:3-11.
25. Loo BW, Shen J, Quinlan-Davidson S, et al. Tumor size is a critical determinant of local control in single fraction stereotactic radiotherapy of pulmonary tumors. Int J Radiat Oncol Biol Phy. 2008;72:S467-S468.
26. Gerszten PC, Ozhasoglu C, Burton S, et al. Cyberknife frameless stereotactic radiosurgery for spinal lesions: clinical experience in 125 cases. Neurosurgery. 2004;55:89-98.
27. Guthrie BL, Adler JR Jr. Computer-assisted preoperative planning, interactive surgery, and frameless stereotaxy. Clin Neurosurg. 1992;38:112-131.
28. Murphy MJ, Cox RS. The accuracy of dose localization for an image-guided frameless radiosurgery system. Med Phys. 1996;23:2043-2049.
29. Adler JR Jr, Chang SD, Murphy MJ, et al. The CyberKnife: a frameless robotic system for radiosurgery. Stereotact Funct Neurosurg. 1997;69:124-128.
30. Chang SD, Main W, Martin DP, et al. An analysis of the accuracy of the CyberKnife: a robotic frameless stereotactic radiosurgical system. Neurosurgery. 2003;52:140-147.
31. Andrade R, Heron DE, Degirmenci B, et al. Post-treatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers. Int J Radiat Oncol Biol Phy. 2006;65: 1315-1322.
32. Tsuchida Y, Therasse P. Response evaluation criteria in solid tumors (RECIST): new guidelines. Med Pediatr Oncol. 2001;37:1-3.
33. Pai P, Chuang C, Wei K, et al. Stereotactic radiosurgery for locally recurrent nasopharyngeal carcinoma. Head Neck. 2002;24:748-753.
34. Chua D, Sham J, Kwan-Ngai H, et al. Salvage treatment for persistent and recurrent T1-2 nasopharyngeal carcinoma by stereotactic radiosurgery. Head Neck. 2001;23:791-798. (Pubitemid 32754870)
35. Ferlito A, Shaha AR, Silver CE, et al. Incidence and sites of distant metastases from head and neck cancer. ORL J Otorhinolaryngol Relat Spec. 2001;63:202-207. (Pubitemid 32620169)
36. Eriksen JG, Steiniche T, Overgaard J. The influence of epidermal growth factor receptor and tumor differentiation on the response to accelerated radiotherapy of squamous cell carcinomas of the head and neck in the randomized DAHANCA 6 and 7 study. Radiother Oncol. 2005;74:93-100.